Uncategorized

March 28th, 2017

FDA Expands Indication for Revlimid® as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Stem Cell Transplant

By

The U.S. Food and Drug Administration (FDA) expanded the existing indication for Revlimid® (lenalidomide) to include use for patients with multiple myeloma as maintenance therapy following autologous stem cell transplant (ASCT). The expanded indication makes Revlimid® the first and only treatment to receive FDA approval for maintenance use following auto-HSCT.1 Autologous stem cell transplant after […]

View full entry

Tags: maintenance, Multiple Myeloma, News, revlimid, secondary cancer, secondary malignancy


March 23rd, 2017

SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers

By

People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name, rare cancers make up more than 20 percent of cancers diagnosed worldwide. The trial is called DART, […]

View full entry

Tags: All Cancer Types, General, immunotherapy, keytruda, Neuroblastoma, News, Other News Topics (not Types of Cancer), Retinoblastoma, Sarcoma, Vaginal Cancer


March 22nd, 2017

Kyprolis® Significantly Improves Overall Survival Compared To Velcade® In Relapsed Or Refractory Multiple Myeloma

By

The ENDEAVOR trial results were updated at the 16th International Myeloma Workshop in New Delhi.  The trial demonstrated that Kyprolis (Carfilzomib) not only significantly extended progression-free survival compared to Velcade (Bortezomib), but also overall improved overall survival, making it a clinically meaningful advance in the treatment of relapsed or refractory multiple myeloma.  Patients with relapsed […]

View full entry

Tags: kyprolis, Multiple Myeloma, News, proteosome inhibitors


March 17th, 2017

Dealing with Distress

By

Why it’s important to acknowledge distress during cancer care and what to do about it By Teresa L. Deshields and Clorinda Walley The moment a patient is diagnosed with cancer, one symptom is likely to surface: distress. Sadness, fear, helplessness, anger, social concerns, depression, anxiety, panic – just about everyone that has cancer suffers distress […]

View full entry

Tags: General, general cancer, News


March 16th, 2017

Kisqali® Receives FDA Approval as First Line Treatment for HR+/HER2- Metastatic Breast Cancer

By

The US Food and Drug Administration (FDA) has approved the investigational drug Kisqali® (ribociclib, LEE011) for first line treatment of hormone receptor + HER 2- metastatic breast cancer because when combined with Femera (letrozole) the combination benefits all such women and leads to improved survival without cancer recurrence. The interim results from a large clinical […]

View full entry

Tags: Breast Cancer, kisqali, Metastatic Breast Cancer, News, riboiclib, Stages II-III Breast Cancer


March 16th, 2017

Regional Chemotherapy Technique for Extremity Sarcoma Salvages Patients’ Limbs from Amputation

By

Patients with a type of advanced malignant cancer of the arms or legs have typically faced amputation of the afflicted limb as the only treatment option.  However, a technique that limits the application of chemotherapy to the cancerous region can preserve limbs in a high percentage of these patients, researchers from five cancer centers in […]

View full entry

Tags: limb perfusion, News, Sarcoma


March 15th, 2017

COMBI-v BRAF/MEK Inhibitor Combination Trial Continues to Impress in Melanoma

By

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology.  The latest data confirm an estimated 45% of patients who received Tafinlar (dabrafenib) + Mekinist (trametinib) combination therapy are alive versus 31% of patients on BRAF monotherapy with […]

View full entry

Tags: BRAF, mek, Mekinist (trametinib), Melanoma, News, Tafinlar (dabrafenib), Zelboraf (vemurafenib


March 13th, 2017

Know Your Treatment Options: Colorectal Cancer Liver Metastases

By

Nearly 136,000 Americans are expected to be diagnosed with colorectal (CRC) cancer this year,1 and more than 50% will have their cancer spread to their liver.2  Many individuals with CRC involving the liver erroneously conclude that they have no treatment options other than systemic therapy.  There are however several therapeutic options for the treatment of […]

View full entry

Tags: Colon Cancer, http://news2017.cancerconsultants.com.php56-17.dfw3-1.websitetestlink.com/, News


March 7th, 2017

Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC

By

The US Food and Drug Administration (FDA) granted Priority Review for the expanded use of Zykadia® (ceritinib) as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. The FDA also granted Breakthrough Therapy designation to Zykadia for the first-line […]

View full entry

Tags: Alk 1, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, Zykadia® ceritinib


March 6th, 2017

New Ovarian Cancer Immunotherapy Study Poses Question: Can Microbiome Influence Treatment Response?

By

A clinical study with Keytruda (pembrolizumab) in a novel untried combination is the first ovarian cancer clinical trial to incorporate gut flora analysis.  Dr. Emese Zsiros, the study’s Principal Investigator, explains a new, unique clinical trial investigating immunotherapy for patients with advanced ovarian cancer. A new clinical study underway at Roswell Park Cancer Institute is […]

View full entry

Tags: Gut Flora, Microbiome, News, Ovarian Cancer


March 6th, 2017

Proton Beam Therapy may Improve Outcomes for Rectal Cancer

By

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum, pancreatic, or small intestine. This treatment approach is often associated with improved outcomes but the radiation may also cause […]

View full entry

Tags: News, proton beam therapy, Rectal Cancer


March 3rd, 2017

Thyroid Cancer Survivors May Have Increased Risk of Osteoporosis and Heart Conditions

By

The results of a recent new study find that younger survivors of thyroid cancer are at increased risk for osteoporosis, high blood pressure and heart disease.  Thyroid cancer is the fifth most common cancer in women. The thyroid gland is a butterfly-shaped organ that is below the Adam’s apple in the front part of the […]

View full entry

Tags: News, osteoporosis, Thyroid Cancer


March 2nd, 2017

Preliminary Results Suggest That Pamrevlumab is Promising in Pancreatic Cancer

By

Updated results from an ongoing clinical study of pamrevlumab (FG-3019) in combination with standard-of-care chemotherapy in patients with locally advanced pancreatic ductal adenocarcinoma were presented during the ASCO 2017 Gastrointestinal Cancers Symposium in San Francisco and appear to suggest pamrevulmab may improve outcomes compared to chemotherapy alone. About Pancreatic Ductal Adenocarcinoma and Connective Tissue Growth […]

View full entry

Tags: connective tissue growth factor, News, Pamrevlumab. FG-3019, Pancreatic Cancer


March 1st, 2017

Xermelo-new option for controlling symptoms of Carcinoid Syndrome

By

The US Food and Drug Administration (FDA) today approved the oral therapy Xermelo (telotristat ethyl) to be used in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhea. Carcinoid syndrome is a cluster of symptoms that occurs in patients with advanced neuroendocrine tumors (NET) and the related diarrhea results […]

View full entry

Tags: carcinoid syndrome, General, NET, neuroendocrine tumors, News, Other News Topics (not Types of Cancer), Xermelo


March 1st, 2017

Dalantercept- Inlyta Shows Promise for Renal Cell Cancer

By

The combination of Inlyta (axitinib) and dalantercept, an activin receptor–like kinase 1 (ALK1) signaling inhibitor appears promising in the treatment of advanced renal cell carcinoma (RCC) according to the results of a recently published Phase I clinical trial.1 According to investigators, 25% of RCC patients responded to treatment with the combination and this represents an […]

View full entry

Tags: activin receptor–like kinase 1 (ALK1) signaling inhibitor renal cell carcinoma (RCC), dalantercept, News, Renal Cancer